{"id":"tcbhp-vs-ddec-thp","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL223253","moleculeType":"Small molecule","molecularWeight":"677.83"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Histone deacetylases are enzymes that remove acetyl groups from histones, leading to chromatin compaction and reduced gene transcription. By inhibiting these enzymes, TCbHP increases the acetylation of histones, resulting in increased gene transcription and potentially leading to the death of cancer cells.","oneSentence":"TCbHP is a histone deacetylase inhibitor, which works by blocking the activity of histone deacetylases to modify gene expression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:34.314Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT05871918","phase":"PHASE3","title":"A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-10-08","conditions":"HER-2 Positive Breast Cancer","enrollment":832}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TCbHP VS ddEC-THP","genericName":"TCbHP VS ddEC-THP","companyName":"Tianjin Medical University Cancer Institute and Hospital","companyId":"tianjin-medical-university-cancer-institute-and-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TCbHP is a histone deacetylase inhibitor, which works by blocking the activity of histone deacetylases to modify gene expression. Used for Metastatic non-small cell lung cancer, Acute myeloid leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}